Day 1 | Day 2 | Download Brochure
WEDNESDAY, JUNE 6
12:30 pm Registration
1:30 Chairperson’s Opening Remarks
Arie Regev, M.D., Hepatology Consultant and Chair, Liver and GI Safety Committee, Global Patient Safety, Eli Lilly and Company
1:40 How to Avoid Being Surprised by Hepatotoxicity at the Final Stages of Drug Development and Approval?
Arie Regev, M.D., Hepatology Consultant and Chair, Liver and GI Safety Committee, Global Patient Safety, Eli Lilly and Company;
» 2:10 KEYNOTE PANEL
Safety in Numbers: Exploring the Pre-Competitive Space
Moderator: Arie Regev, M.D., Eli Lilly and Company
Panelists:
Paul B. Watkins, M.D., Director, Hamner-UNC Institute for Drug Safety Sciences, Verne S. Caviness Distinguished Professor of Medicine, University of North Carolina at Chapel Hill
Richard Miller, D.V.M., Ph.D., DipACVP, Vice President, Safety Assessment, GlaxoSmithKline, Inc.;
Stephane Dhalluin, Ph.D., Director, Investigative Non-Clinical Safety, UCB Pharma
Gerry Kenna, Ph.D., Principal Scientist, Hepatic Target Organ Strategy Lead, Safety Assessment, Molecular Toxicology, AstraZeneca
|
3:10 Sponsored Presentations (Opportunities Available)
3:40 Refreshment Break in the Exhibit Hall with Poster Viewing
4:10 Can Biologicals Cause Liver Toxicity?
Paul Vancutsem, D.V.M., Ph.D., Director of Toxicology, Biogen Idec
4:40 Interactive Discussion Groups
Concurrent problem-solving discussions on specific topics, to provide a forum for exchanging ideas, voicing opinions and meeting potential collaborators. Discussions will be led by a moderator/s, limited to 15 participants per table, and open to all attendees and exhibitors.
5:40 End of Day
Day 1 | Day 2 | Download Brochure